To include your compound in the COVID-19 Resource Center, submit it here.

Axokine: REGN began a U.S. double-blind, placebo-controlled Phase III trial in up to 180 overweight and obese individuals with Type II diabetes. The trial is th

Regeneron Pharmaceuticals Inc. (REGN), Tarrytown, N.Y.
Product: Axokine
Business: Metabolic
Therapeutic category: Metabolism, Growth factor
Target:

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE